-
公开(公告)号：EP2318416A1
公开(公告)日：2011-05-11
申请号：EP09788008.2
申请日：2009-07-24
IPC分类号： C07D513/10 , A61K31/547 , A61P25/28
CPC分类号： C07D513/10
摘要： A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type dementia.
摘要翻译： 由通式（I）表示的化合物：或其药学上可接受的盐，具有Aβ产生抑制效果或BACE1一个抑制作用，是作为用于神经变性疾病由Aβ引起和由Alzheimer-为代表的预防或治疗剂有用的 型痴呆。
-
公开(公告)号：EP3052496B1
公开(公告)日：2018-11-28
申请号：EP14799529.4
申请日：2014-09-30
发明人： PAYNE, Andrew , CASTRO PINEIRO, Jose Luis , BIRCH, Louise Michelle , KHAN, Afzal , BRAUNTON, Alan James , KITULAGODA, James Edward , SOEJIMA, Motohiro
IPC分类号： C07D471/04 , A61K31/437 , A61P25/00
CPC分类号： C07D471/04 , C07D401/04
摘要： 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
-
公开(公告)号：EP3052496A1
公开(公告)日：2016-08-10
申请号：EP14799529.4
申请日：2014-09-30
发明人： PAYNE, Andrew , CASTRO PINEIRO, Jose Luis , BIRCH, Louise Michelle , KHAN, Afzal , BRAUNTON, Alan James , KITULAGODA, James Edward , SOEJIMA, Motohiro
IPC分类号： C07D471/04 , A61K31/437 , A61P25/00
CPC分类号： C07D471/04 , C07D401/04
摘要： 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
摘要翻译： 作为毒蕈碱性乙酰胆碱受体（mAChR）M1的调节剂的4-氮杂吲哚衍生物，其可用于预防或疾病改善或对症治疗与神经系统疾病如阿尔茨海默氏型痴呆（AD）或路易体痴呆相关的认知缺陷 （DLB）和包含4-氮杂吲哚衍生物作为活性成分的药物组合物。
-
公开(公告)号：EP2318416B1
公开(公告)日：2013-09-04
申请号：EP09788008.2
申请日：2009-07-24
IPC分类号： C07D513/10 , A61K31/547 , A61P25/28
CPC分类号： C07D513/10
-
公开(公告)号：EP2233474A1
公开(公告)日：2010-09-29
申请号：EP09701914.5
申请日：2009-01-16
发明人： SUZUKI, Yuichi , MOTOKI, Takafumi , KANEKO, Toshihiko , TAKAISHI, Mamoru , ISHIDA, Tasuku , TAKEDA, Kunitoshi , KITA, Yoichi , YAMAMOTO, Noboru , KHAN, Afzal , DIMOPOULOS, Paschalis
IPC分类号： C07D279/08 , A61K31/4439 , A61K31/5415 , A61K31/542 , A61P25/28 , A61P43/00 , C07D417/10 , C07D417/12 , C07D513/04
CPC分类号： A61K31/542 , C07D279/08 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
摘要： A compound represented by the general formula:
or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is -NR e CO- or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.摘要翻译： 由通式表示的化合物或其药学上可接受的盐或其溶剂合物，其中环A为C 6-14芳基等，L为-NR e CO-等（其中R e为 氢原子等），环B为C 6-14芳基等，X为C 1-3亚烷基等，Y为单键等，Z为C 1-3 亚烷基等，R 1和R 2各自独立地为氢原子等，R 3，R 4，R 5和R 6独立地为氢原子，卤素原子等，具有A 2生成 抑制作用或BACE1抑制作用，可用作由A 2引起的以阿尔茨海默氏型痴呆为代表的神经变性疾病的预防或治疗剂。
-
6.发明公开THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE 审中-公开在C-Jun N末端激酶的抑制的7-氮杂吲哚USE
公开(公告)号：EP2125801A1
公开(公告)日：2009-12-02
申请号：EP08708724.3
申请日：2008-02-05
发明人： GRACZYK, Piotr Pawel , DIMOPOULOS, Paschalis , FARTHING, Christopher Neil , BHATIA, Gurpreet Singh , KHAN, Afzal
IPC分类号： C07D471/04 , A61K31/437 , A61P25/28
CPC分类号： C07D471/04
摘要： The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
-
公开(公告)号：EP3489237B1
公开(公告)日：2020-05-13
申请号：EP18204685.4
申请日：2014-09-30
发明人： PAYNE, Andrew , CASTRO PINEIRO, Jose Luis , BIRCH, Louise Michelle , KHAN, Afzal , BRAUNTON, Alan James , KITULAGODA, James Edward , SOEJIMA, Motohiro
IPC分类号： C07D471/04 , A61K31/437 , A61P25/00
-
公开(公告)号：EP3489237A1
公开(公告)日：2019-05-29
申请号：EP18204685.4
申请日：2014-09-30
发明人： PAYNE, Andrew , CASTRO PINEIRO, Jose Luis , BIRCH, Louise Michelle , KHAN, Afzal , BRAUNTON, Alan James , KITULAGODA, James Edward , SOEJIMA, Motohiro
IPC分类号： C07D471/04 , A61K31/437 , A61P25/00
摘要： 4-Azaindole derivative as shown below or a pharmaceutically acceptable salt thereof which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition thereof as an active ingredient.
-
公开(公告)号：EP2233474B1
公开(公告)日：2015-08-05
申请号：EP09701914.5
申请日：2009-01-16
发明人： SUZUKI, Yuichi , MOTOKI, Takafumi , KANEKO, Toshihiko , TAKAISHI, Mamoru , ISHIDA, Tasuku , TAKEDA, Kunitoshi , KITA, Yoichi , YAMAMOTO, Noboru , KHAN, Afzal , DIMOPOULOS, Paschalis
IPC分类号： C07D279/08 , A61K31/4439 , A61K31/5415 , A61K31/542 , A61P25/28 , A61P43/00 , C07D417/10 , C07D417/12 , C07D513/04 , C07D417/14
CPC分类号： A61K31/542 , C07D279/08 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.028 秒)
